A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
Open Access
- 7 June 2021
- journal article
- research article
- Published by Elsevier BV in European Urology Open Science
- Vol. 29, 59-67
- https://doi.org/10.1016/j.euros.2021.05.003
Abstract
No abstract availableFunding Information
- Astellas Pharma
This publication has 30 references indexed in Scilit:
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Accuracy of First and Second Generation Testosterone Assays and Improvement through Sample ExtractionClinical Chemistry, 2012
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in BoneJournal of Clinical Oncology, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate CancerCancer Research, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate CancerCancer Research, 2007
- Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate CancerJAMA, 1991